PTC Therapeutics board approves $500 million stock buyback
PTC Therapeutics said on November 3, 2026, that its board cleared a program to repurchase up to $500 million in common stock as conditions allow.
SEC filing
3 stories
PTC Therapeutics said on November 3, 2026, that its board cleared a program to repurchase up to $500 million in common stock as conditions allow.
SEC filing
PTC lifted its full-year revenue outlook on Sephience growth while reporting new timelines for its ST-920 gene therapy, votoplam and vatiquinone programs.
SEC filing
The one-time AAV gene therapy is headed toward a rolling BLA submission expected to finish in the fourth quarter of 2026.
SEC filing